Back to discover
Disease

Chronic Kidney Disease-Mineral and Bone Disorder

Late-stage therapeutic developmentEmerging research
MeSHChronic Kidney Disease-Mineral and Bone Disorder
1
Publications
24
Clinical trials
2008
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Chronic kidney disease mineral and bone disorder in children.

Research2007-11-28Pediatric nephrology (Berlin, Germany)

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q3 2028.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
DAPARHT: DAPAgliflozin for Renal Protection in Heart Transplant Recipients
Results expected Q3 20282026-07-01
Upcoming trial readoutHigh impact
Safety and Immunogenicity of Shingrix in Renal Transplant Recipients
Results expected Q2 20292026-04-08
Clinical Milestones7View
Results expected 4
Recently completed 2
Other updates 1
Activity timeline7

Clinical trials

18 sponsors · 0 new · 2 completed in the last 12 months (net -1)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

Phase 3 · Recruiting · Steno Diabetes Center Copenhagen

Safety and Immunogenicity of Shingrix in Renal Transplant Recipients

Phase 3 · Recruiting · University of Colorado, Denver

Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease

Phase 3 · Recruiting · Alessandro Doria

Phase 3, Randomized, Open-label, Controlled, Multiple Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 Days to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis

Phase 3 · Recruiting · Amgen

DAPARHT: DAPAgliflozin for Renal Protection in Heart Transplant Recipients

Phase 3 · Active, not recruiting · Oslo University Hospital

Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Patients With Chronic Kidney Disease

Phase 4 · Recruiting · Ditte Hansen
Recruiting

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

Phase 3 · Recruiting · Steno Diabetes Center Copenhagen

Safety and Immunogenicity of Shingrix in Renal Transplant Recipients

Phase 3 · Recruiting · University of Colorado, Denver

Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease

Phase 3 · Recruiting · Alessandro Doria

Phase 3, Randomized, Open-label, Controlled, Multiple Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 Days to < 18 Years of Age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis

Phase 3 · Recruiting · Amgen

Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Patients With Chronic Kidney Disease

Phase 4 · Recruiting · Ditte Hansen
Recently completed

Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

Phase 3 · Completed · The George Institute

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Dose-Titrated PLS240 in the Treatment of Secondary Hyperparathyroidism in Individuals With End Stage Kidney Disease on Hemodialysis (PATH-2) With an Open-Label Extension

Phase 3 · Completed · Pathalys Pharma

A Phase 3, Prospective, Randomized, Multicenter, Single-blind, Controlled Study Evaluating Arteriovenous Fistula Outcomes With and Without a Perivascular Sirolimus Eluting Collagen Implant (The ACCESS 2 Trial)

Phase 3 · Completed · Vascular Therapies, Inc.

An Open Label, Multi-Center, Safety and Pharmacokinetic Bridging Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring in Normal and Renal Compromised Subjects for the Evaluation of Kidney Function

Phase 3 · Completed · MediBeacon

Randomized, Multicenter, Open-label, Comparative Study of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI), Associating Myfortic ® and Neoral ® Compared to a CNI-free Treatment, Combining Myfortic ® and Certican ® , in Adult Patients With de Novo Renal Transplant

Phase 3 · Completed · Centre Hospitalier Universitaire, Amiens

Pharmacokinetics of Meropenem and Aztreonam After Intraperitoneal Administration Via Cycler-therapy in APD Patients Without Peritonitis

Phase 2/3 · Completed · Karl Landsteiner Insitute for Nephrology and Haemato-Oncology

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Chronic kidney disease mineral and bone disorder in children.

Pediatric nephrology (Berlin, Germany) · 2008 · 47 cites
Recent publications

Chronic kidney disease mineral and bone disorder in children.

Pediatric nephrology (Berlin, Germany) · 2008 · 47 cites
Leading journals1
  • Pediatric nephrology (Berlin, Germany)1
Leading researchers3
  • Bakkaloglu S1
  • Salusky I1
  • Wesseling K1
Affiliations (unnormalised)1
  • David Geffen School of Medicine at UCLA1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders.

Identifiers
MeSHChronic Kidney Disease-Mineral and Bone Disorder
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.